Current Treatment for chronic hepatitis C
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology
Link
http://link.springer.com/content/pdf/10.1007/s11938-004-0008-2.pdf
Reference42 articles.
1. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975–982. Randomized, controlled, multinational phase III registration trial. The combination of peginterferon alfa-2a (40 kD) plus ribavirin was significantly more effective than conventional interferon plus ribavirin or peginterferon alfa-2a (40 kD) monotherapy
2. Hadziyannis SJ, Sette H, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346–355. Randomized, controlled, multinational phase III registration trial of peginterferon alfa-2a (40 kD) plus ribavirin that employed an innovative 2 × 2 factorial design. The study examined the effect of treatment duration and ribavirin dose on SVR rates according to HCV genotype. Current treatment recommendations are based on the results of this trial.
3. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358: 958–965. The first randomized, controlled, multinational phase III registration trial of a pegylated interferon plus ribavirin. The combination of pegylated interferon alfa-2b (12 kD) plus ribavirin was significantly more effective than conventional interferon plus ribavirin.
4. Zeuzem S, Diago M, Gane E, et al.: International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) [abstract 106]. Hepatology, 2003 384(Suppl 1): 208A.
5. Ahmed A, Keeffe EB: Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004, 126: 1409–1415. Excellent recent review.
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Negative Effect of Epstein-Barr Virus on the Response of Hepatitis C Virus Patients to Interferon-ribavirin Therapy;Journal of Pure and Applied Microbiology;2019-06-30
2. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients;World Journal of Gastroenterology;2013
3. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy;Journal of Gastroenterology and Hepatology;2010-12-22
4. Long-Term Efficacy of Pegylated Interferon Alpha-2a in HCV-Positive Hemodialysis Patients;Renal Failure;2008-02
5. Heart Transplantation;Surgery;2008
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3